// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Effect of baricitinib on functional impairment in RA patients with moderate disease activity and an inadequate response to conventional DMARDs

Bruce Kirkham - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Baricitinib

The potential role of pharmacy staff in reducing patient delay in consulting with symptoms of RA

Gwenda Simons - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Cardiovascular risk knowledge in patients of South Asian origin living with rheumatoid arthritis: data from India and the UK

Kanta Kumar - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Efficacy and safety of filgotinib for patients with RA with inadequate response to methotrexate: FINCH1 primary outcome results

David Walker - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Methotrexate

Indirect measurement of central sensitisation as a predictor of response to different drug treatments in patients with inflammatory arthritis in a UK clinical cohort

Stephanie Santos-Paulo - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

The effect of body weight in response to subcutaneous tocilizumab in patients with RA

Rebecca Davies - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Tocilizumab

Preliminary results: driving improvements in disease outcomes for rheumatoid arthritis patients using remote disease activity monitoring via smartphone app

Amy C. B MacBrayne - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Filgotinib, a janus kinase 1 selective inhibitor, modulates disease-associated cytokines in patients with active RA

Peter C Taylor - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Filgotinib

Effects of filgotinib on anaemia, thrombocytopoenia and leukopoenia: results from a Phase 3 study in patients with active RA and prior inadequate response or intolerance to bDMARDs

David Walker - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Filgotinib

Efficacy and safety of filgotinib for patients with RA naïve to MTX therapy: FINCH3 primary outcome results

Neil McKay - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Filgotinib

Interrogation of transcriptome data in RA for identifying disease susceptibility loci and predictors of treatment response

Rhodri Smith - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Long-term safety of filgotinib in patients with PsA: week 52 safety data from a Phase 2 open-label extension study

Laura Coates - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Filgotinib

An updated safety profile of baricitinib for the treatment of RA up to 7 years

David Walker - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Baricitinib

Treatment fidelity in the Gait Rehabilitation in Early Rheumatoid Arthritis Trial (GREAT) feasibility study

Emma Godfrey - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Vitamin D in early rheumatoid arthritis

Stephanie R Harrison - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Inflammatory Arthritis

Ergocalciferol

Influence of ambient air pollution on RA disease activity scores

Ahmad R Alsaber - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

A matching-adjusted indirect comparison (MAIC) of upadacitinib versus tofacitinib in csDMARD-IR patients with moderate to severe RA

Christopher Edwards - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Methotrexate

Remote monitoring of patients with RA: a user-centred design approach

Melanie J Martin - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Obstetrics/Gynecology

Rheumatoid arthritis

N/A

Risk of sinusitis in patients with rheumatoid arthritis: association with different treatment strategies

Kapil Halai - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

The impact of early RA on lower limb kinematics

Alexander G Izod - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved